Clinical data | |
---|---|
Trade names | Glufast |
AHFS/Drugs.com | International Drug Names |
Routes of administration | By mouth (tablets) |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H25NO3 |
Molar mass | 315.413 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Mitiglinide (INN,[1] trade name Glufast) is a drug for the treatment of type 2 diabetes.[2]
Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.